BR112015024871A2 - composto, diastereoisômero ou epímero, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção - Google Patents

composto, diastereoisômero ou epímero, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção

Info

Publication number
BR112015024871A2
BR112015024871A2 BR112015024871A BR112015024871A BR112015024871A2 BR 112015024871 A2 BR112015024871 A2 BR 112015024871A2 BR 112015024871 A BR112015024871 A BR 112015024871A BR 112015024871 A BR112015024871 A BR 112015024871A BR 112015024871 A2 BR112015024871 A2 BR 112015024871A2
Authority
BR
Brazil
Prior art keywords
compound
diastereoisomer
infection
treating
pharmaceutical composition
Prior art date
Application number
BR112015024871A
Other languages
English (en)
Inventor
Luther Anatol
Obrecht Daniel
Bernardini Francesca
Zbinden Peter
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of BR112015024871A2 publication Critical patent/BR112015024871A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)

Abstract

1 / 1 resumo “composto, diastereoisã”mero ou epãmero, composiã‡ãƒo farmacãšutica, uso de um composto, e, mã‰todo para tratamento de uma infecã‡ãƒo” 1 peptidomimã©ticos grampo beta da fã³rmula (1) geral, ciclo(p - 2 3 4 5 6 7 8 9 10 11 12 1 2 p -p -p -p -p - p p p -p -p -p -t -t ] e sais aceitã¡veis farmaceuticamente 1 12 1 2 dos mesmos, com p a p , t e t sendo elementos como definidos na descriã§ã£o e nas reivindicaã§ãµes, tem ampla atividade antimicrobiana de espectro gram-negativo para, por exemplo, inibir o crescimento ou eliminar microrganismos tal como klebsiella pneumoniae e/ou acinetobacter baumannii e/ou escherichia coli. eles podem ser usados como medicamentos para tratar ou prevenir infecã§ãµes ou desinfetantes para gãªneros alimentã­cios, cosmã©ticos, medicamentos ou outros materiais contendo nutrientes. esses peptidomimã©ticos podem ser fabricados por um processo o qual ã© baseado em uma estratã©gia de sã­ntese em fase de mistura sã³lida e soluã§ã£o.
BR112015024871A 2013-03-30 2014-03-28 composto, diastereoisômero ou epímero, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção BR112015024871A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13001657 2013-03-30
PCT/EP2014/056285 WO2014161782A1 (en) 2013-03-30 2014-03-28 Beta-hairpin peptidomimetics

Publications (1)

Publication Number Publication Date
BR112015024871A2 true BR112015024871A2 (pt) 2017-07-18

Family

ID=48039984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024871A BR112015024871A2 (pt) 2013-03-30 2014-03-28 composto, diastereoisômero ou epímero, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção

Country Status (19)

Country Link
US (2) US9850284B2 (pt)
EP (1) EP2978772B1 (pt)
JP (2) JP6785652B2 (pt)
KR (1) KR102279427B1 (pt)
CN (1) CN105849119B (pt)
AU (1) AU2014247189C1 (pt)
BR (1) BR112015024871A2 (pt)
CA (1) CA2908388C (pt)
DK (1) DK2978772T3 (pt)
EA (1) EA035407B1 (pt)
ES (1) ES2691895T3 (pt)
HK (1) HK1225399A1 (pt)
IL (1) IL241821B (pt)
MX (2) MX366089B (pt)
NZ (1) NZ712736A (pt)
PT (1) PT2978772T (pt)
SG (1) SG11201507977UA (pt)
WO (1) WO2014161782A1 (pt)
ZA (1) ZA201507350B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017583B1 (ru) 2007-02-28 2013-01-30 Полифор Лтд. Закрепленные на матрице пептидомиметики
JP6917886B2 (ja) * 2014-09-30 2021-08-11 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ ベータ−ヘアピンペプチド模倣体
WO2016050361A1 (en) * 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
CA2979437A1 (en) 2015-03-23 2016-09-29 Polyphor Ag Beta-hairpin peptidomimetics
JP7312167B2 (ja) * 2017-11-10 2023-07-20 スペクシス アーゲー ベータヘアピンペプチド模倣物
JP2021007675A (ja) 2019-07-02 2021-01-28 日本光電工業株式会社 医用フォトメータ
WO2023227771A1 (en) 2022-05-27 2023-11-30 Fundación Privada Instituto De Salud Global Barcelona Cyclic peptides with antibacterial activity against multidrug resistant (mdr) pathogens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255428C (zh) * 2001-02-23 2006-05-10 波利弗尔有限公司 具有抗微生物活性的模板固定化肽模拟物
CA2496215C (en) * 2002-08-20 2013-07-16 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
WO2007079597A1 (en) * 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
WO2012016595A1 (en) * 2010-08-05 2012-02-09 Polyphor Ag β-HAIRPIN PEPTIDOMIMETICS

Also Published As

Publication number Publication date
US20160060298A1 (en) 2016-03-03
AU2014247189B2 (en) 2018-12-13
AU2014247189A1 (en) 2015-10-22
EA201591895A1 (ru) 2016-02-29
MX2015013762A (es) 2016-02-26
AU2014247189C1 (en) 2019-05-16
US10370412B2 (en) 2019-08-06
CA2908388C (en) 2022-07-12
CA2908388A1 (en) 2014-10-09
NZ712736A (en) 2021-07-30
IL241821B (en) 2019-06-30
MX366089B (es) 2019-06-27
DK2978772T3 (en) 2018-10-15
SG11201507977UA (en) 2015-10-29
PT2978772T (pt) 2018-11-08
ZA201507350B (en) 2017-07-26
CN105849119A (zh) 2016-08-10
US20180072776A1 (en) 2018-03-15
HK1225399A1 (zh) 2017-09-08
EP2978772A1 (en) 2016-02-03
US9850284B2 (en) 2017-12-26
KR102279427B1 (ko) 2021-07-20
EA035407B1 (ru) 2020-06-09
JP2016518346A (ja) 2016-06-23
MX2019002658A (es) 2019-07-15
JP6785652B2 (ja) 2020-11-18
KR20150139896A (ko) 2015-12-14
CN105849119B (zh) 2021-01-19
EP2978772B1 (en) 2018-06-27
JP2019123717A (ja) 2019-07-25
ES2691895T3 (es) 2018-11-29
WO2014161782A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
BR112015024871A2 (pt) composto, diastereoisômero ou epímero, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção
BR112015024939A2 (pt) composto, diastereoisômero ou epímero de um composto, composição farmacêutica, uso de um composto, processo para a preparação de um composto, e, método para tratamento de uma infecção
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
MX2009005603A (es) Compuestos de urea policiclicos antibacterianos.
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
BR112013005426A2 (pt) "composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação."
BR112014023321A2 (pt) Composições compreendendo fagos antibacterianos e seus usos
BR112013003045A2 (pt) composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração
MX2013010552A (es) Compuestos de guanidina.
BR112015011158A8 (pt) triazolopirazina, seu uso e preparação farmacêutica
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
BRPI0923326A2 (pt) Composto, composição farmacêutica, métodos para inibir girasse de dna bacteriana e/ou topisomerase iv bacteriana, para produzir um efeito antibacteriano em um animal de sangue quente, e para tratar uma infecção bacteriana, uso de um composto, e, processo para preparar um composto.
BR112012024691A2 (pt) composto, e, composição farmacêutica
BR112016016854A2 (pt) Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados
BR112013025275A2 (pt) derivados de cefalosporina e suas composições farmacêuticas
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
BR112017020315A2 (pt) compostos, diastereoisômeros ou epímeros, composição farmacêutica, uso e processo de preparação de compostos
BR112018068347A2 (pt) compostos de cinolin-4-amina e seu uso no tratamento de câncer
BR112015006243A2 (pt) agentes antibacterianos de fenicol
WO2014145713A3 (en) Aminoglycoside antibiotics with reduced ototoxicity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements